p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 470-479

  Clahsen, Pieter C ^a   Van De Velde, Cornelis J ^a   Duval, Christian ^a   Pallud, Claude ^a   Mandard, Anne Marie ^a   Delobelle Deroide, Alice ^a   Van Den Broek, Lambert ^a   Sahmoud, Tarek M ^a   Van De Vijver, Marc J ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; ADULT; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; EARLY DIAGNOSIS; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PERIOPERATIVE PERIOD; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TISSUE SECTION;

EID: 0031919283     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.470     Document Type: Article

References (42)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339:1-15, 71-85, 1992
2. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326:1756-1761, 1992
3. Wood WC: Integration of risk factors to allow patient selection for adjuvant systemic therapy in lymph node-negative breast cancer patients. World J Surg 18:39-44, 1994
4. Allred DC, Clark GM, Tandon AK, et al: Her-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
5. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
6. Nordenskjöld B, Stål O, Skoog L, et al: S-phase fraction and c-erbB-2 expression related to the survival benefit from adjuvant chemotherapy of breast cancer. Proc Am Soc Clin Oncol 13:67, 1994 (abstr)
7. Muss HB, Thor AD, Berry DA, et al: c-erfeB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
8. Osborne RJ, Merlo GR, Mitsudomi T, et al: Mutations in the p53 gene in primary human breast cancers. Cancer Res 51:6194-6198, 1991
9. Varley JM, Brammar WJ, Lane DP, et al: Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 6:413-421, 1991
10. Coles C, Condie A, Chetty U, et al: p53 mutations in breast cancer. Cancer Res 52:5291-5298, 1992
11. Baas IO, Mulder JR, Offerhaus JA, et al: An evaluation of six antibodies for immunohistochemistry of mutant P53 gene product in archival colorectal neoplasms. J Pathol 172:5-12, 1994
12. Cornelis RS, van Vliet M, Vos CBJ, et al: Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumours without p53 mutations. Cancer Res 54:1-7, 1994
13. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
14. Clahsen PC, van de Velde CJH, Julien JP, et al: Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 12:1266-1271, 1994
15. Bloom HJG, Richardson WW: Histological grading and progno3 sis in breast cancer: A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359-377, 1957
16. Berg FM, Baas IO, Polak MM, et al: Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinoma using a novel target unmasking fluid. Am J Pathol 142:381-385, 1993
17. van de Vijver MJ, Peterse JL, Mooi WJ, et al: Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245, 1988
18. Cattoretti G, Pileri S, Parravicini C, et al: Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 171:83-98, 1993
19. Wintzer H-O, Zipfel I, Schulte-Mönting J, et al: Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67:421-428, 1991
20. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
21. Horak ER, Leek R, Klenk N, et al: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124, 1992
22. Byar DP: Identification of prognostic factors, in, Buyse ME, Staquet MJ, Sylvester RJ, (eds): Cancer Clinical Trials. Methods and Practice. Oxford, United Kingdom, Oxford Medical, 1998, pp 423-443
23. Veronese SM, Gambacorta M, Gottardi O, et al: Proliferation index as a prognostic marker in breast cancer. Cancer 71:3926-3931, 1993
24. Bouzubar N, Walker KJ, Griffiths K, et al: Ki67 immunostaining in primary breast cancer: Pathological and clinical associations. Br J Cancer 59:943-947, 1989
25. EORTC Breast Cancer Cooperative Group: Manual for Clinical Research in Breast Cancer. Leuven, Belgium, EORTC Monograph, 1991
26. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
28. Cox DR: Regression models and life-tables. J R Stat Assoc B 34:187-220, 1972
29. Breslow N: Comparison of survival curves, in, Buyse ME, Staquet MJ, Sylvester RJ, (eds): Cancer Clinical Trials. Methods and Practice. Oxford, United Kingdom, Oxford Medical, 1988, pp 382-406 30. Cary, NC SAS Institute
30. Levine AJ: The p53 tumor suppressor gene. N Engl J Med 326:1350-1352, 1992
31. Dittmer D, Pati S, Zambetti G, et al: Gain of function mutations in p53. Nat Genet 4:42-46, 1993
32. Chin KV, Ueda K, Pastan I, et al: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459-462, 1992
33. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327, 1994
34. Isola J, Visakorpi T, Holli K, et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992
35. Silvestrini R, Benini E, Daidone MG, et al: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965-970, 1993
36. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Instit 85:200-206, 1993
37. Barnes DM, Dublin EA, Fisher CJ, et al: Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis? Hum Pathol 24:469-476, 1993
38. Thor AD, Moore DH II, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
39. Gasparini G, Weidner N, Bevilacqua P, et al: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454-466, 1994
40. Elledge RM, Gray R, Mansour E, et al: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87:1254-1256, 1995
41. van de Velde CJH, Julien J-P, Tubiana-Hulin M, et al: Preoperative chemotherapy in operable breast cancer (POCOB), the influence of timing FEC in relation to surgery. Ann Oncol 3:202, 1992 (suppl 5, abstr)
42. Yusuf S, Wittes J, Probstfield J, et al: Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 266:93-98, 1991